Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

NNC 0141-0000-0100 · NNC 0141

Other · developed by Innate Pharma

Phase 1 Most advanced trial (none active)
IPHA Developer
1 Registered trials

What is NNC 0141-0000-0100?

NNC 0141-0000-0100 (NNC 0141) is a drug given subcutaneously or intravenously in single and multiple-dose study cohorts. It is studied in inflammation and rheumatoid arthritis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NNC 0141
Drug type
Other
Therapy area
Immunology
Developer
Innate Pharma (IPHA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01370902 Phase 1 Inflammation Completed IPHA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

InflammationRheumatoid Arthritis

More from Innate Pharma

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the IPHA page.

Follow IPHA, the company behind NNC 0141-0000-0100

See IPHA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IPHA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.